A Phase II, Multi-center, Open-label Study Evaluating the Efficacy and Safety of GRN1005 in Non-Small Cell Lung Cancer Patients With Brain Metastases.

Trial Profile

A Phase II, Multi-center, Open-label Study Evaluating the Efficacy and Safety of GRN1005 in Non-Small Cell Lung Cancer Patients With Brain Metastases.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2015

At a glance

  • Drugs Paclitaxel trevatide (Primary)
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms GRABM-L
  • Sponsors AngioChem
  • Most Recent Events

    • 30 May 2013 Additional lead trial centre added as reported by ClinicalTrials.gov record.
    • 03 Dec 2012 Status changed from recruiting to discontinued.
    • 14 Jun 2012 Additional lead trial investigator (Jeffrey J. Raizer) added as reported by Robert H. Lurie Comprehensive Cancer Center, Northwestern University record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top